Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316523 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01316523 is a Phase 2 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 30 participants.
The verdict
NCT01316523, a Phase 2 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treatment of multiple myeloma and myelodysplastic syndrome. Rituximab is effective as a single agent and in combination with chemotherapy for indolent Non-Hodgkin's Lymphoma. The purpose of this study is to see how well giving lenalidomide together with rituximab works in treating patients with previously untreated indolent Non Hodgkin's Lymphoma. Lenalidomide will taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, unacceptable side effects or after twelve cycles if the patient is responding well. Rituximab 375 mg/m2/wk x 4 weeks will begin on Day 15 of cycle 1. After 4 cycles of therapy, if patients respond well to treatment, patients will receive a second course of Rituximab. Blood samples will be collected to assess how the immune system is functioning.
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-12 |
| Est. Completion | 2024-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316523
The ClinicalTrials.gov registry entry for NCT01316523 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01316523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316523 about?
NCT01316523 is a clinical study titled "Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma". Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treatment of multiple myeloma and myelodysplastic syndrome. Rituximab is effective as a single agent and in combination with chemotherapy for indolent Non-Hodgkin's Lymphoma. The pu...
What is the current status of trial NCT01316523?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-12. Estimated completion is 2024-04-14.
What interventions are being tested in trial NCT01316523?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01316523?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.